NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma

The authors demonstrated that NOTCH1, an understudied oncogene in hepatocellular carcinoma, elicits sexually dimorphic anti-tumor immunity and response to FDA-approved immunotherapies.